Loading organizations...
Norcliffe Capital operates as an investment firm, offering access to tax-efficient investment opportunities. The company focuses capital deployment into the life science and disruptive technology sectors, particularly targeting ventures developing life-changing medical innovations. It connects high-net-worth investors with curated opportunities in these specialized, high-growth domains, enabling strategic financial participation.
Founded in late 2014, Norcliffe Capital arose from the clear need for structured, tax-efficient investment vehicles within the burgeoning medical technology and disruptive technology landscapes. Its initial vision centered on bridging private capital with innovative enterprises, allowing investors to support groundbreaking advancements while optimizing financial returns.
The firm primarily serves high-net-worth individuals seeking to invest in impactful industries. Norcliffe Capital's mission is to foster innovation by channeling essential investment into companies poised to make significant societal contributions through scientific and technological breakthroughs. Its long-term vision involves continuously identifying and presenting opportunities aligning with investor objectives and transformative impact.
Norcliffe Capital has 2 tracked investments across 2 companies. The latest tracked deal is $27.1M Seed Extension in Laverock Therapeutics in June 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 30, 2025 | Laverock Therapeutics | $27.1M Seed Extension | Elizabeth Klein | ELI Lilly And Company, EOS Advisory, Maven Capital Partners, Mercia Ventures |
| Apr 1, 2021 | Oxford Endovascular | $10.0M Series A | Parkwalk Advisors, Martin Diggle | Borealis Ventures, Oxford Science Enterprises, University OF Oxford, Additio Investment Group, Oxford Investment Consultants, Perivoli Innovations |
